BackFlexion Therapeutics Overview

Flexion Therapeutics Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$14.77M
46.36% YoY

As of Sep 30, 2021

Annual R&D Expenses (TTM)

$52.08M
14.35% YoY

Trailing 12 months ending Sep 30, 2021

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Flexion Therapeutics (FLXN) FAQ

Stockcircle tracks research & development for Flexion Therapeutics (FLXN), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Flexion Therapeutics's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main FLXN overview so you can move from this figure to the surrounding analysis quickly.